This proposal seeks funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to develop AI-driven voice biomarkers for the early detection of Alzheimer’s disease (AD). Our interdisciplinary team at the University of South Florida, through the Bridge2AI-Voice consortium, aims to leverage non-invasive voice analysis to detect early cognitive decline, by creating a dataset that could facilitate scalable and accessible alternatives to current diagnostic methods.

Key objectives include collecting voice samples from high-risk participants including individuals with mild cognitive impairment or subjective cognitive decline, as well as individuals diagnosed with dementia or Alzheimer's Disease. The project also emphasizes ethical AI development through transparent practices and community collaboration, aligning with the mission of Bridge2AI-Voice.

By accelerating the discovery of voice-based biomarkers, this initiative will create cost-effective, accessible screening tools for Alzheimer’s disease. With ADDF’s support, we aim to improve early detection and empower patients and healthcare providers with innovative tools for better outcomes.